Pharmacokinetics of Hydrocortisone After Subcutaneous Administration in Chronic Adrenal Insufficiency

Model scores of the 29,894 trials active now.

Model score 12% for any early termination, 8% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 9% of the time (111 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2012-07-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Design: crossover (lowers risk) · Design
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 2 (raises risk) · Design
• Sponsor's past termination rate: no earlier finished trials (lowers risk) · Sponsor's track record
• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: chronicbreaststudy drugdiabetesdisease
  Phrases that lowered it: and safetysafety ofpharmacokineticswayis conducted
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Has a data monitoring committee: Yes (raises risk) · Design
• Responsible party: sponsor investigator (raises risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Drug's FAERS reports with a death: 14.3% (lowers risk) · Drug's FDA history
• Number of arms: 2 (raises risk) · Design
• Maximum age: 64 (lowers risk) · Who can join
• Minimum age: 18 (raises risk) · Who can join
• Disease area, neurology: No (lowers risk) · Disease area
• Primary purpose: treatment (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 0 (raises risk) · Sponsor's track record
• Blinding: none (raises risk) · Design
• Drug's FAERS reports marked serious: 85.0% (raises risk) · Drug's FDA history
• Collaborators: 0 (raises risk) · Design
• Drug's FAERS reports before start: 13262 (raises risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Vaginal Prednisone Administration for Prevention of Adrenal Crisis NCT02689960 · started 2017 · scored riskier than 16% of active trials completed
• Ultradian Subcutaneous Hydrocortisone Infusion in Addison Disease and Congenital Adrenal Hyperplasia NCT02096510 · started 2014 · scored riskier than 13% of active trials completed
• Glucocorticoid Treatment in Addison's Disease NCT01063569 · started 2010 · scored riskier than 20% of active trials completed
• Subcutaneous Hydrocortisone Children With Congenital Adrenal Hyperplasia NCT03718234 · started 2019 · scored riskier than 13% of active trials completed
• Effects of Steroid Replacement Therapy on Metabolic, Cardiovascular and Bone Outcomes in Adrenal Insufficiency NCT06260462 · started 2012 · scored riskier than 8% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.